Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple scler… Read more
Zenas BioPharma, Inc. Common Stock (ZBIO) - Total Assets
Latest total assets as of September 2025: $322.02 Million USD
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) holds total assets worth $322.02 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zenas BioPharma, Inc. Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Zenas BioPharma, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zenas BioPharma, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Zenas BioPharma, Inc. Common Stock's total assets of $322.02 Million consist of 96.2% current assets and 3.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zenas BioPharma, Inc. Common Stock's current assets represent 96.2% of total assets in 2024, an increase from 91.8% in 2022.
- Cash Position: Cash and equivalents constituted 86.4% of total assets in 2024, down from 90.1% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Zenas BioPharma, Inc. Common Stock Competitors by Total Assets
Key competitors of Zenas BioPharma, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Zenas BioPharma, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zenas BioPharma, Inc. Common Stock generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Zenas BioPharma, Inc. Common Stock is currently not profitable relative to its asset base.
Zenas BioPharma, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.66 | 8.95 | 2.64 |
| Quick Ratio | 5.66 | 8.95 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $244.22 Million | $ 349.78 Million | $ 42.48 Million |
Zenas BioPharma, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Zenas BioPharma, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.14 |
| Latest Market Cap to Assets Ratio | 2.01 |
| Asset Growth Rate (YoY) | 442.6% |
| Total Assets | $369.97 Million |
| Market Capitalization | $745.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Zenas BioPharma, Inc. Common Stock's assets at a significant premium ( 2.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Zenas BioPharma, Inc. Common Stock's assets grew by 442.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zenas BioPharma, Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Zenas BioPharma, Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $369.97 Million | +442.63% |
| 2023-12-31 | $68.18 Million | -8.58% |
| 2022-12-31 | $74.58 Million | -- |